These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34107351)

  • 1. Latest progress in the study of nanoparticle-based delivery of the CRISPR/Cas9 system.
    Yu M; Liu X; Cheng H; Kuang L; Zhang S; Yan X
    Methods; 2021 Oct; 194():48-55. PubMed ID: 34107351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA.
    Miller JB; Zhang S; Kos P; Xiong H; Zhou K; Perelman SS; Zhu H; Siegwart DJ
    Angew Chem Int Ed Engl; 2017 Jan; 56(4):1059-1063. PubMed ID: 27981708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing.
    Finn JD; Smith AR; Patel MC; Shaw L; Youniss MR; van Heteren J; Dirstine T; Ciullo C; Lescarbeau R; Seitzer J; Shah RR; Shah A; Ling D; Growe J; Pink M; Rohde E; Wood KM; Salomon WE; Harrington WF; Dombrowski C; Strapps WR; Chang Y; Morrissey DV
    Cell Rep; 2018 Feb; 22(9):2227-2235. PubMed ID: 29490262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
    Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
    Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
    Wilbie D; Walther J; Mastrobattista E
    Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.
    Givens BE; Naguib YW; Geary SM; Devor EJ; Salem AK
    AAPS J; 2018 Oct; 20(6):108. PubMed ID: 30306365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas9 Delivery by Artificial Virus (RRPHC).
    Yang S; Wu Q; Wei Y; Gong C
    Methods Mol Biol; 2019; 1961():81-91. PubMed ID: 30912041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome Editing with CRISPR-Cas9: Can It Get Any Better?
    Haeussler M; Concordet JP
    J Genet Genomics; 2016 May; 43(5):239-50. PubMed ID: 27210042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.
    Liu C; Zhang L; Liu H; Cheng K
    J Control Release; 2017 Nov; 266():17-26. PubMed ID: 28911805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.
    Zhang S; Shen J; Li D; Cheng Y
    Theranostics; 2021; 11(2):614-648. PubMed ID: 33391496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components.
    Kazemian P; Yu SY; Thomson SB; Birkenshaw A; Leavitt BR; Ross CJD
    Mol Pharm; 2022 Jun; 19(6):1669-1686. PubMed ID: 35594500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smart Strategies for Precise Delivery of CRISPR/Cas9 in Genome Editing.
    Hasanzadeh A; Noori H; Jahandideh A; Haeri Moghaddam N; Kamrani Mousavi SM; Nourizadeh H; Saeedi S; Karimi M; Hamblin MR
    ACS Appl Bio Mater; 2022 Feb; 5(2):413-437. PubMed ID: 35040621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Near-infrared upconversion-activated CRISPR-Cas9 system: A remote-controlled gene editing platform.
    Pan Y; Yang J; Luan X; Liu X; Li X; Yang J; Huang T; Sun L; Wang Y; Lin Y; Song Y
    Sci Adv; 2019 Apr; 5(4):eaav7199. PubMed ID: 30949579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors.
    Nie D; Guo T; Yue M; Li W; Zong X; Zhu Y; Huang J; Lin M
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and Efficient Gene Deletion by CRISPR/Cas9.
    Neldeborg S; Lin L; Stougaard M; Luo Y
    Methods Mol Biol; 2019; 1961():233-247. PubMed ID: 30912049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Robust Protocol for CRISPR-Cas9 Gene Editing in Human Suspension Cell Lines.
    Wardyn JD; Chan ASY; Jeyasekharan AD
    Curr Protoc; 2021 Nov; 1(11):e286. PubMed ID: 34748280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Versatile modification of the CRISPR/Cas9 ribonucleoprotein system to facilitate in vivo application.
    Sun B; Chen H; Gao X
    J Control Release; 2021 Sep; 337():698-717. PubMed ID: 34364918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of ionizable lipid nanoparticles and a lyophilized formulation for potent CRISPR-Cas9 delivery and genome editing.
    Sun Q; Zhang H; Ding F; Gao X; Zhu Z; Yang C
    Int J Pharm; 2024 Mar; 652():123845. PubMed ID: 38266942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances of Cas9/sgRNA delivery system for gene editing].
    Hu X; Wang S; Yu L; Zhang X; Chen W
    Sheng Wu Gong Cheng Xue Bao; 2021 Nov; 37(11):3880-3889. PubMed ID: 34841792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.